Product Introduction
Bioactivity


英文名: GW1929

描述: GW1929是PPAR-γ有效激動劑，對人PPAR-γ的pKi 為8.84。對人和鼠的pEC50分別為8.56 和 8.27。

細(xì)胞實(shí)驗(yàn): For the experiments, the cells are plated in 96-well plates at a density of 2 × 10^5 cells per cm2 and cultured in the presence of TBBPA, in concentrations ranging from 1 nM to 100 μM TBBPA. TBBPA is dissolved in DMSO, resulting in a final vehicle concentration of 0.1 % (v/v). Control (no vehicle) and DMSO-treated wells are included in the experimental design to determine the effect of DMSO. To study whether PPAR-γ is involved in the neurotoxic effect of TBBPA, cells are co-treated with 10 μM TBBPA and 10 μM GW1929 or GW9662. After 6 or 24 h of culture, 100 μL medium is collected for the LDH analysis, and the cells are collected and frozen at ?70°C for the caspase-3 activity measurements [2].

激酶實(shí)驗(yàn): Ligand binding to bacterially expressed ligand-binding domain (LBD) of hPPAR-γ is determined by the scintillation proximity assay (SPA). The assay measures the ability of putative ligands to displace receptor-bound [3H]BRL 49653. Assays are conducted in 96-well plates. Wells contained varying concentrations of GW1929 or troglitazone; streptavidin-modified SPA beads to which biotinylated PPAR-γ LBD is prebound; and 10 nM of the specific radioligand [3H]BRL 49653 in a volume of 100 μL. The amount of nonspecific binding, as assessed by control wells that contained 50 μM of the corresponding unlabeled ligand, is subtracted from each data point. For each compound tested, plots of ligand concentration versus counts/min of radioligand bound are constructed, and apparent Ki values are estimated from a nonlinear least-squares fit of the data, assuming simple competitive binding. The results are expressed as pKi, where pKi = -log10(KI) [1].

動物實(shí)驗(yàn): Animals are housed at 72°F and 50% relative humidity with a 12-h light and dark cycle and fed Formulab Diet 5008. Age- (60-day) and glucose-matched male Zucker diabetic fatty rats are gavaged twice daily for 14 days with vehicle (0.05 M N-methylglucamine), GW1929 (0.5, 1.0, or 5.0 mg/kg), or troglitazone (as the milled extrudate, in a suspension in methylcellulose, 50, 150, and 500 mg/kg). Another group of animals receives a mixture of Humulin N and Humulin R by subcutaneous injection twice daily. On days 7 and 14 of dosing, nonfasted measurements of glucose, lactate, insulin, total cholesterol, TGs, F FAs, and hematocrit are obtained. On day 14 of dosing, samples for serum drug levels (2-h postdose) and glycosylated hemoglobin measurements are also collected. In addition, once weekly, three animals from each group are placed in metabolic chambers for 48 h for quantitation of 24-h food and water consumption. Body weights are recorded throughout the study. At the conclusion of the study, perfused pancreas experiments are performed on 12 animals (n = 4 per group) that have received either GW1929 (1 and 5 mg/kg) or vehicle, to directly evaluate the effects of treatment on basal and glucose-stimulated insulin secretion. The remaining animals are killed, and their pancreases are processed for immunocytochemistry [1].

體外活性: GW1929是一種強(qiáng)效的PPAR-γ激活劑，對人類和小鼠的PPAR-γ的pEC50分別為8.56和8.27，同時對人類PPAR-γ、PPAR-α和PPAR-δ的pKis分別為8.84、小于5.5和小于6.5[1]。在濃度為10μM時，GW1929能夠抑制TBBPA誘導(dǎo)的新皮層細(xì)胞培養(yǎng)中caspase-3的增加和TBBPA刺激的LDH釋放[2]。

體內(nèi)活性: GW1929（0.5、1、5 mg/kg，p.o.）在治療14天后顯著降低了Zucker糖尿病肥胖（ZDF）大鼠的非空腹血糖水平，并具有抗脂解作用。在ZDF大鼠中，GW1929（1、5 mg/kg，p.o.）增強(qiáng)了β細(xì)胞對葡萄糖刺激的胰島素分泌能力[1]。

存儲條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 33 mg/mL (66.59 mM)


關(guān)鍵字: GW1929 | Peroxisome proliferator-activated receptors | PPAR | GW 1929 | GW-1929 | inhibit | Inhibitor

相關(guān)產(chǎn)品: Licarin B | Repaglinide | Chiglitazar | Choline Fenofibrate | Darglitazone | Imiglitazar | (S)-(+)-Ibuprofen | Ragaglitazar | Cinnamyl alcohol | CC618

相關(guān)庫: Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library | Lipid Metabolism Compound Library | Metabolism Compound Library | Anti-Pancreatic Cancer Compound Library | Preclinical Compound Library | Stem Cell Differentiation Compound Library | Covalent Inhibitor Library | Anti-Cardiovascular Disease Compound Library | Bioactive Compound Library

TargetMol（陶術(shù)）作為一家全球性的生物醫(yī)藥領(lǐng)域高科技企業(yè)，我們致力于為高校、研究所、醫(yī)院、企業(yè)等各類生物醫(yī)藥研發(fā)機(jī)構(gòu)提供優(yōu)質(zhì)的產(chǎn)品和服務(wù)，為全球醫(yī)藥科學(xué)家更高效地完成科研工作助力�？商峁�20,000+種 抑制劑和激動劑 、800+種 化合物庫 、19,000+種 天然產(chǎn)物 ，以及9,000+種 重組蛋白 、多種 多肽 、抗體 和 生命科學(xué)試劑盒 等。此外，在上海，TargetMol研發(fā)中心配備了 CADD & AIDD研究中心、藥理實(shí)驗(yàn)室和藥物化學(xué)合成 平臺三大技術(shù)中心，可提供虛擬篩選、化合物活性測試、分子間結(jié)合力檢測和化合物結(jié)構(gòu)優(yōu)化等技術(shù)服務(wù)，多方位滿足用戶的研發(fā)需求。